Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Inventiva S.A. (IVA)

6.175   -0.255 (-3.97%) 02-03 15:00
Open: 6.2495 Pre. Close: 6.43
High: 6.45 Low: 6.175
Volume: 1,767 Market Cap: 260(M)

Technical analysis

as of: 2023-02-03 3:18:21 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 7.96     One year: 9.3
Support: Support1: 5.26    Support2: 4.3
Resistance: Resistance1: 6.82    Resistance2: 7.96
Pivot: 6.17
Moving Average: MA(5): 6.09     MA(20): 5.93
MA(100): 4.83     MA(250): 6.91
MACD: MACD(12,26): 0.3     Signal(9): 0.3
Stochastic oscillator: %K(14,3): 49.6     %D(3): 54.1
RSI: RSI(14): 60.8
52-week: High: 13.65  Low: 3.49
Average Vol(K): 3-Month: 8 (K)  10-Days: 4 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ IVA ] has closed above bottom band by 49.4%. Bollinger Bands are 66.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.46 - 6.5 6.5 - 6.54
Low: 6 - 6.04 6.04 - 6.08
Close: 6.03 - 6.1 6.1 - 6.16

Company Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Headline News

Fri, 03 Feb 2023
Iva Sanders Obituary (1933 - 2023) -

Thu, 02 Feb 2023
Iva Smith Obituary (1937 - 2023) -

Wed, 01 Feb 2023
Iva Jean (Wisdom) Smith - WCLU

Wed, 01 Feb 2023
"We Initially Imagined It as a Rectangle That From the Left Starts Off ... - Filmmaker Magazine

Wed, 01 Feb 2023
Iva Morris Obituary (2023) -

Tue, 31 Jan 2023
Arts Society of Kingston welcomes February with performance by Iva Bittová, Timothy Hill, three new exhibitions - The Daily Freeman

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 42 (M)
Shares Float 8 (M)
% Held by Insiders 0 (%)
% Held by Institutions 23.4 (%)
Shares Short 192 (K)
Shares Short P.Month 194 (K)

Stock Financials

EPS -1.34
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.64
Profit Margin (%) 0
Operating Margin (%) -636.8
Return on Assets (ttm) -34.4
Return on Equity (ttm) -70.8
Qtrly Rev. Growth -11.9
Gross Profit (p.s.) 0.17
Sales Per Share 0.23
EBITDA (p.s.) -1.46
Qtrly Earnings Growth 0
Operating Cash Flow -54 (M)
Levered Free Cash Flow -39 (M)

Stock Valuations

PE Ratio -4.65
PEG Ratio 0
Price to Book value 3.74
Price to Sales 26.7
Price to Cash Flow -4.82

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.